Brendan N Putko1, Haran Yogasundaram1, Kelvin Chow2, Joseph Pagano2, Aneal Khan3, D Ian Paterson1, Richard B Thompson2, Gavin Y Oudit4. 1. Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, 2C2 Walter Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada. 2. Department of Biomedical Engineering, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. 3. Department of Medical Genetics and Pediatrics, University of Calgary, Calgary, Alberta, Canada. 4. Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, 2C2 Walter Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada gavin.oudit@ualberta.ca.
Abstract
AIMS: Anderson-Fabry Disease (AFD) is an important cause of cardiomyopathy characterized by concentric left-ventricular hypertrophy (LVH). We evaluated the extent of left-atrial (LA) structural and functional remodelling in this group of patients given that LA remodelling is a marker of adverse outcomes in the presence of LVH. METHODS AND RESULTS: Clinical profiles were obtained and cardiac MRI was performed in cohorts of patients with AFD (n = 31), healthy controls (n = 23), and a positive control cohort with known concentric remodelling and LVH (CR/H, n = 21). Of patients with AFD, 58% were on enzyme-replacement therapy (ERT), 84% were on renin-angiotensin system antagonism, and 65% were on statins. Despite a similar increase in LV mass index in the AFD when compared with the CR/H cohort, mean LA volumes for the AFD group were similar to those seen in the healthy control group. Following from this, we observed that the percentage contribution to LV stroke volume due to elastic/passive and active LA emptying was similar in the AFD and healthy control groups, while passive emptying was significantly lower in the CR/H group. The consequences of LVH in the AFD cohort were manifested in atrioventricular uncoupling, whereby the extent of elastic/passive and active LA emptying was not a function of the extent of longitudinal movement of the mitral annular plane, as it was in healthy control subjects. CONCLUSION: Left-atrial structure and function were relatively normal in our cohort of patients with AFD, who were also judiciously treated with a contemporary strategy that includes renin-angiotensin system antagonism, statins, and ERT. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Anderson-Fabry Disease (AFD) is an important cause of cardiomyopathy characterized by concentric left-ventricular hypertrophy (LVH). We evaluated the extent of left-atrial (LA) structural and functional remodelling in this group of patients given that LA remodelling is a marker of adverse outcomes in the presence of LVH. METHODS AND RESULTS: Clinical profiles were obtained and cardiac MRI was performed in cohorts of patients with AFD (n = 31), healthy controls (n = 23), and a positive control cohort with known concentric remodelling and LVH (CR/H, n = 21). Of patients with AFD, 58% were on enzyme-replacement therapy (ERT), 84% were on renin-angiotensin system antagonism, and 65% were on statins. Despite a similar increase in LV mass index in the AFD when compared with the CR/H cohort, mean LA volumes for the AFD group were similar to those seen in the healthy control group. Following from this, we observed that the percentage contribution to LV stroke volume due to elastic/passive and active LA emptying was similar in the AFD and healthy control groups, while passive emptying was significantly lower in the CR/H group. The consequences of LVH in the AFD cohort were manifested in atrioventricular uncoupling, whereby the extent of elastic/passive and active LA emptying was not a function of the extent of longitudinal movement of the mitral annular plane, as it was in healthy control subjects. CONCLUSION: Left-atrial structure and function were relatively normal in our cohort of patients with AFD, who were also judiciously treated with a contemporary strategy that includes renin-angiotensin system antagonism, statins, and ERT. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Sachin Gupta; Susan A Matulevicius; Colby R Ayers; Jarett D Berry; Parag C Patel; David W Markham; Benjamin D Levine; Kelly M Chin; James A de Lemos; Ronald M Peshock; Mark H Drazner Journal: Eur Heart J Date: 2012-07-10 Impact factor: 29.983
Authors: Gustavo G Blume; Christopher J Mcleod; Marion E Barnes; James B Seward; Patricia A Pellikka; Paul M Bastiansen; Teresa S M Tsang Journal: Eur J Echocardiogr Date: 2011-05-12
Authors: Zsuzsanna Hollander; Darlene L Y Dai; Brendan N Putko; Haran Yogasundaram; Janet E Wilson-McManus; Richard B Thompson; Aneal Khan; Michael L West; Bruce M McManus; Gavin Y Oudit Journal: Eur J Heart Fail Date: 2015-01-23 Impact factor: 15.534
Authors: Leopoldo Perez de Isla; Gisela Feltes; Joel Moreno; Wilfredo Martinez; Adriana Saltijeral; Jose A de Agustin; Jose Juan Gomez de Diego; Pedro Marcos-Alberca; María Luaces; Joaquin Ferreiros; Miguel Angel Garcia Fernandez; Carlos Macaya Journal: Eur Heart J Cardiovasc Imaging Date: 2014-01-30 Impact factor: 6.875
Authors: June Cheng-Baron; Kelvin Chow; Joseph J Pagano; Kumaradevan Punithakumar; D Ian Paterson; Gavin Y Oudit; Richard B Thompson Journal: Magn Reson Med Date: 2014-03-13 Impact factor: 4.668
Authors: Anderson C Armstrong; Kiang Liu; Cora E Lewis; Stephen Sidney; Laura A Colangelo; Satoru Kishi; Bharath Ambale-Venkatesh; Alex Arynchyn; David R Jacobs; Luís C L Correia; Samuel S Gidding; João A C Lima Journal: Eur Heart J Cardiovasc Imaging Date: 2014-02-16 Impact factor: 6.875
Authors: Justin A Ezekowitz; Harald Becher; Israel Belenkie; Alexander M Clark; Henry J Duff; Matthias G Friedrich; Mark J Haykowsky; Jonathan G Howlett; Zamaneh Kassiri; Padma Kaul; Daniel H Kim; Merril L Knudtson; Peter E Light; Gary D Lopaschuk; Finlay A McAlister; Michelle L Noga; Gavin Y Oudit; D Ian Paterson; Hude Quan; Richard Schulz; Richard B Thompson; Sarah G Weeks; Todd J Anderson; Jason R B Dyck Journal: BMC Cardiovasc Disord Date: 2014-07-25 Impact factor: 2.298
Authors: Francesco Bandera; Anita Mollo; Matteo Frigelli; Giulia Guglielmi; Nicoletta Ventrella; Maria Concetta Pastore; Matteo Cameli; Marco Guazzi Journal: Front Cardiovasc Med Date: 2022-01-13
Authors: Joseph J Pagano; Kelvin Chow; Aneal Khan; Evangelos Michelakis; Ian Paterson; Gavin Y Oudit; Richard B Thompson Journal: PLoS One Date: 2016-06-15 Impact factor: 3.240